Results 91 to 100 of about 10,710,575 (236)
Breast Cancer Tissue Bank Search Tool
The Research Query page is a component of the Breast Cancer Tissue Bank website. It shows the numbers of consented patients, and the numbers of available samples.
core
The tumor microenvironment (TME) harbors diverse immune cell states that shape therapeutic outcomes in breast cancer. Here, we identify a conserved stress‐programmed cellular module as a key responder to neoadjuvant therapies in breast cancer ...
Zhibo Shao +18 more
doaj +1 more source
Background: Trastuzumab deruxtecan (T-DXd) has demonstrated transformative efficacy in HER2-positive metastatic breast cancer (MBC), and induction–maintenance strategies with T-DXd are under investigation to optimize the treatments.
Yukinori Ozaki +20 more
doaj +1 more source
Background The trial aimed to evaluate the efficacy and safety of pyrotinib in combination with trastuzumab, nab-paclitaxel, and carboplatin (TCbHPy) in the neoadjuvant setting (ChiCTR2100043523), as well as the role of metabolites in predicting the ...
Mei Liu +10 more
doaj +1 more source
Cancer Trends: Breast cancer 1994-2016
There were 62,052 cases of newly diagnosed invasive or in situ breast tumours registered in Ireland by the National Cancer Registry for the period 1994–2016, of which 56,366 were invasive (ICD10: C50) and 5,686 were carcinoma in situ (ICD10: D05 ...
National Cancer Registry Ireland (NCRI)
core
BCTB Invasive Breast Cancer Samples and Images
This BCTB subcollection contains breast tissue and blood samples, and associated images, where a diagnosis of invasive cancer has been determined by a ...
core
Background Chidamide is an oral subtype-selective histone deacetylase inhibitor that has been used as an anti-cancer agent. This study evaluated the efficacy and safety of chidamide plus fulvestrant in the treatment of HR-positive and HER2-negative ...
La Zou +8 more
doaj +1 more source
Purpose This study aimed to evaluate the efficacy and safety of docetaxel rechallenge in HER2-negative metastatic breast cancer (MBC) patients who discontinued docetaxel for reasons other than disease progression.
Hui-Ai Zeng +7 more
doaj +1 more source

